Nafisah B. Atako

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer.

Journal: The Journal of clinical investigation
Published: March 31, 2026

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Journal: The Journal of clinical investigation
Published: March 31, 2026

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.

Journal: Cell
Published: January 23, 2025

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.

Journal: The Lancet. Digital health
Published: January 10, 2024

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.

Journal: Research square
Published: February 17, 2023

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Journal: Lancet (London, England)
Published: October 12, 2021

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.

Journal: JCO precision oncology
Published: November 01, 2020

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

Journal: Trials
Published: August 10, 2018

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

Journal: The Lancet. Respiratory medicine
Published: July 13, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026